Physician profile
Chris A Clark
NPI 1760457857
$1,146.50
in general payments reported to CMS, 2019-2025
15 companies · $60.33 in 2025
The $60.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $39.07 · 2021: $31.56 · 2022: $202 · 2023: $212 · 2024: $182 · 2025: $60.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.99 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $212.33 | 2019-2024 | Veozah |
| Abbvie INC. | $163.30 | 2022-2023 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $159.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $131.89 | 2019-2025 | Bexsero, Shingrix, Pediarix |
| Abbott Laboratories | $104.18 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $78.62 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $63.29 | 2019-2023 | |
| Novo Nordisk INC | $57.69 | 2020-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $55.18 | 2019 | |
| Dynavax Technologies Corporation | $35.69 | 2022-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $26.08 | 2019-2025 | Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $20.80 | 2024 | Spravato |
| Medtronic, INC. | $14.43 | 2022 | |
| Dexcom, INC. | $13.91 | 2022 | |
| Organon LLC | $10.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.